Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1665262

registered interest
date	17/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to paragraph 16 of Annex B of the Impact Assessment for the Statutory Scheme – Branded Medicines Pricing, what the evidential basis is for the assessment that the resources deployed through pharmaceutical investment would come to the UK in another form; and whether his Department has made an assessment of the potential efficiency of alternative deployment of resources.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	203129
answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>The approach to assessing the potential impacts on investment within the statutory scheme’s impact assessment followed well established precedent and is in-line with the Green Book paragraphs 6.5 and 6.6. As such the impact assessment considers spill-over benefits of investment, with a literature review suggesting an estimated mean benefit of 34% of the overall investment, but does not account for these within the net present value calculation due to investment being one of several possible company responses to change in profitability.</p><p>We are in the process of analysing the responses provided to the consultation on this statutory scheme and will update on our preferred policy approach later this year.</p><p>Regarding alternative deployment of resource, by controlling growth in the cost of medicines we ensure value for money for the taxpayer and enable the National Health Service to continue investing in patient access to new medicines. Any additional spending on medicines may come at the cost of other equally (or more) effective healthcare spending.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/10/2023 09:39:09 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1663753

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the cap mechanism in the Voluntary Scheme for Branded Medicines Pricing and Access on (a) levels of investment in late stage clinical trials and (b) decisions taken by pharmaceutical companies regarding (i) whether and (ii) when to launch medicines in the UK.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	201606
answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>The Government has assessed the link between the cap mechanism in our medicine pricing schemes and various kinds of investment in our impact assessment of recent updates to the statutory scheme for branded medicines pricing, which operates alongside the voluntary scheme for branded medicines pricing and access (VPAS). The Government’s 2023 impact assessment of updates to the statutory scheme is available at the following link:</p><p><a href="https://www.gov.uk/government/consultations/proposed-update-to-the-2023-statutory-scheme-to-control-the-costs-of-branded-health-service-medicines" target="_blank">https://www.gov.uk/government/consultations/proposed-update-to-the-2023-statutory-scheme-to-control-the-costs-of-branded-health-service-medicines</a></p><p>The Government is working to better understand the impacts the operation of the current VPAS on the United Kingdom’s life sciences industry. We are in direct conversations with pharmaceutical companies, including in the recent pre-negotiation workshops, as well as the Department for Science Innovation and Technology, and Department for Business and Trade about the business environment for life sciences.</p><p>Controlling medicine spend is a key departmental aim for both current and future schemes to improve patient outcomes by simplifying, streamlining, and improving access, pricing, and uptake arrangements for cost effective medicines, and deliver faster adoption of most clinically and cost-effective medicines.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/10/2023 13:17:55 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1663754

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the proposed update to the 2023 statutory scheme to control the cost of branded health services medicines, whether other policy options were included on his Department's long-list as alternatives to those included in the final consultation.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	201607
answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>The statutory scheme consultation sets out the options under consideration. We are in the process of analysing the responses provided, including consideration of any alternative options proposed, and will update on our preferred policy approach later this year.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 16:11:00 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1663755

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the proposed update to the 2023 statutory scheme to control the cost of branded health services medicines, what (a) evidential basis and (b) analysis his Department considered when proposing to keep growth in the branded medicines bill in real terms decline, at 2 per cent per annum.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	201608
answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>The Government is currently consulting on updates to the statutory scheme to make sure that the scheme can continue to meet its objectives from 2024 onwards. The evidential basis and analysis considered is set out in the consultation stage impact assessment of the proposed updates that has been published, which is available at the following link:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1179564/impact-assessment-review-scheme-cost-branded-medicines-updated-21-august-2023.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1179564/impact-assessment-review-scheme-cost-branded-medicines-updated-21-august-2023.pdf</a></p><p>2% allowed growth per annum represents an 80% rise in allowed growth compared to the 1.1% per annum which applied from 2019 to 2023. The proposal is consistent with the approach that underpinned the current statutory scheme’s 1.1% allowed growth, i.e., it equals the average allowed growth of the preceding voluntary scheme. The Government welcomes responses on all aspects of this consultation. The impact assessment will be updated with consideration to evidence provided by companies and other stakeholders when the Department publishes its consultation response.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/10/2023 09:35:06 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1663756

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to refer the Impact Assessment for the 2023 statutory scheme to control the cost of branded health services medicines to the Regulatory Policy Committee.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	201609
answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>There are no plans to refer the statutory scheme Impact Assessment to the Regulatory Policy Committee. The proposals only impact companies which choose to sell to the National Health Service and are therefore considered to be in connection with procurement. Given this, the statutory exclusion from the Better Regulation Framework “Procurement 22(4)(b)” applies as confirmed previously by the Economic and Domestic Affairs Secretariat at Cabinet Office.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/10/2023 09:17:48 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1663838

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Epilepsy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of including policies on epilepsy in the the Major Conditions Strategy.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	201691
answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>The Major Conditions Strategy will cover cancers, cardiovascular disease, chronic respiratory disease, dementia, mental ill health and musculoskeletal conditions as these are the six groups of conditions that contribute the most to mortality and morbidity. We expect the approach to tackling these conditions as set out in the report, Major conditions Strategy: a case for change and our strategic framework may have a positive impact on patients with other conditions, including epilepsy.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/10/2023 09:19:02 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1663933

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make it his policy to require breast cancer screening invitations to include an appointment time.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	201786
answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>During the COVID-19 pandemic, timed appointments were no longer deemed feasible for the recovery of services, based on expert opinion. Services moved to an ‘open appointment’ system where women contacted services to agree a time slot suitable for them.</p><p>All services have now recovered, and some have returned to the timed appointments. Several services have retained an open system as they have noted increased uptake and patient satisfaction.</p><p>NHS England have commissioned a series of national evaluative projects being led by Professor Stephen Duffy and his team at Queen Mary’s University of London, to provide evidence to inform NHS England on the most appropriate invitation methodology to underpin future pathway changes and improvements in the national screening programme. These are due to report March 2024.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 11:16:33 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1656996

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Vorasidenib
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) Servier and (b) the MHRA about making Vorasidenib available to clinically suitable brain tumour patients in the UK under the Early Access to Medicines Scheme
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	196642
answer	answer is ministerial correction date of answer 06/09/2023 answer text <p>The Secretary of State and the Department have had no specific discussions with Servier about making Vorasidenib available to clinically suitable brain tumour patients in the United Kingdom under the Early Access to Medicines Scheme (EAMS).</p><p>The Medicines and Healthcare Products Regulatory Agency (MHRA) has also not had any specific discussions with the Secretary of State regarding Vorasidenib. The MHRA has not issued a scientific opinion for Vorasidenib under EAMS but should an application for this be received, the MHRA will consider this accordingly.</p> answering member constituency Colchester answering member printed Will Quince question first answered 06/09/2023 09:27:46 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1651871

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Restless Legs Sydrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many cases of (a) restless leg syndrome and (b) periodic leg movement disorder have been diagnosed in each of the last five years.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	193408
answer	answer is ministerial correction date of answer 13/07/2023 answer text <p>Information specific to restless leg syndrome and periodic leg movement disorder is not collected centrally. Whilst information is collected, on specified extrapyramidal and movement disorders, which would include restless leg syndrome and periodic leg movement disorder, that data is not limited to these conditions and, therefore, would be an overcount.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/07/2023 15:58:10 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1651872

registered interest
date	11/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Restless Legs Sydrome: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the efficacy of prescribed medications for (a) restless leg syndrome and (b) periodic leg movement disorder.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	193409
answer	answer is ministerial correction date of answer 17/07/2023 answer text <p>Before a medicine is licenced, an assessment of quality, safety and efficacy data is carried out by the Medicines and Healthcare Products Regulatory Agency (MHRA). A Marketing Authorisation will only be granted if the overall benefit of taking the medicine outweighs any risks. Licensed medicines that are indicated for the treatment of restless leg syndrome include ropinirole, pramipexole and rotigotine.</p><p>The restless leg syndrome indication for oxycodone/naloxone combination products was reviewed as part of the Commission on Human Medicines’ Opioid Expert Working Group review of dependence and addiction with opioid medicines in 2019. The review concluded that that oxycodone/naloxone was effective in the treatment of restless leg syndrome and that there had been a lack of evidence of harm from the use of oxycodone/naloxone in this indication.</p><p>Following approval, the safety of the medicine is monitored by the MHRA using the Yellow Card scheme. Should it come to the attention of the MHRA that the efficacy of a medicine is reduced, the MHRA are able to review and take appropriate action as necessary. Product information of drugs approved by the MHRA, and public assessment reports, are available on the MHRA website, which is available at the following link:</p><p><a href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fproducts.mhra.gov.uk%2F&amp;data=05%7C01%7CmhraPQPOmailbox%40mhra.gov.uk%7C82b1dc5806e54abcfe3808db83cdcb24%7Ce527ea5c62584cd2a27f8bd237ec4c26%7C0%7C0%7C638248692112205097%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=H2wVK3bHzHzPya9Hyt5O00%2FSnUy72u6Chtf96bIZiEU%3D&amp;reserved=0" target="_blank">https://products.mhra.gov.uk/</a></p> answering member constituency Colchester answering member printed Will Quince question first answered 17/07/2023 14:27:36 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper